Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Mrunali R. Patel, Rashmin B. Patel, Shivam D. Thakore & Ajay B. Solanki. (2020) Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia. Pharmaceutical Development and Technology 25:8, pages 1018-1030.
Read now
Read now
Renee-Marie Ragguett & Roger S. McIntyre. (2019) Cariprazine for the treatment of bipolar depression: a review. Expert Review of Neurotherapeutics 19:4, pages 317-323.
Read now
Read now
Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter & Antony Loebel. (2018) Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. The World Journal of Biological Psychiatry 19:8, pages 586-601.
Read now
Read now
L. Orsolini, C. Tomasetti, A. Valchera, R. Vecchiotti, I. Matarazzo, F. Vellante, F. Iasevoli, E. F. Buonaguro, M. Fornaro, A. L. C. Fiengo, G. Martinotti, M. Mazza, G. Perna, A. Carano, A. De Bartolomeis, M. Di Giannantonio & D. De Berardis. (2016) An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety 15:10, pages 1329-1347.
Read now
Read now
Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge & Thilo Deckersbach. (2015) Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric Disease and Treatment 11, pages 2143-2152.
Read now
Read now
Ricardo P Garay, Ludovic Samalin, Ahcène Hameg & Pierre-Michel Llorca. (2015) Investigational drugs for anxiety in patients with schizophrenia. Expert Opinion on Investigational Drugs 24:4, pages 507-517.
Read now
Read now
Young Sup Woo, Hee Ryung Wang & Won-Myong Bahk. (2013) Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric Disease and Treatment 9, pages 1521-1529.
Read now
Read now
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2012) Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric Disease and Treatment 8, pages 155-168.
Read now
Read now
Norio Yasui-Furukori. (2012) Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Design, Development and Therapy 6, pages 107-115.
Read now
Read now
Joshua T Kantrowitz & Leslie Citrome. (2012) Lurasidone for schizophrenia: what’s different?. Expert Review of Neurotherapeutics 12:3, pages 265-273.
Read now
Read now
Articles from other publishers (18)
Martin Tarzian, Majd Soudan, Muhammed Alhajji, Mariana Ndrio & Adegbenro O Fakoya. (2023) Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy. Cureus.
Crossref
Crossref
Marco Andrea Riva, Umberto Albert, Sergio de Filippis, Antonio Vita & Domenico De Berardis. (2021) Identification of clinical phenotypes in schizophrenia: the role of lurasidone. Therapeutic Advances in Psychopharmacology 11, pages 204512532110122.
Crossref
Crossref
Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath & Rituparna Maiti. (2020) Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. Psychopharmacology 237:11, pages 3471-3480.
Crossref
Crossref
Tatiana Karpouzian-Rogers, Jane Stocks, Herbert Y. Meltzer & James L. Reilly. (2020) The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. Schizophrenia Research 215, pages 314-321.
Crossref
Crossref
Victoria Bell, Henry Dunne, Tharun Zacharia, Katrina Brooker & Sukhi Shergill. (2018) A symptom-based approach to treatment of psychosis in autism spectrum disorder. BJPsych Open 4:1, pages 1-4.
Crossref
Crossref
Chaoying Hu, Yijun Wang, Rong Song, Chen Yu, Xiaoyan Luo & Jingying Jia. (2017) Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clinical Drug Investigation 37:9, pages 861-871.
Crossref
Crossref
Rafał R. Jaeschke, Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Krzysztof Styczeń & Wojciech Datka. (2016) Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports 68:4, pages 748-755.
Crossref
Crossref
Donna Ames, Sian M. Carr-Lopez, Mary A. Gutierrez, Joseph M. Pierre, Jennifer A. Rosen, Susan Shakib & Lynn M. Yudofsky. (2016) Detecting and Managing Adverse Effects of Antipsychotic Medications. Psychiatric Clinics of North America 39:2, pages 275-311.
Crossref
Crossref
L. Samalin, M. Honciuc & P.-M. Llorca. (2015) Efficacité et tolérance à long terme de la lurasidone dans la prise en charge de la schizophrénie. L'Encéphale 41:6, pages 541-549.
Crossref
Crossref
L. Samalin, M. Ben Gharbia, M. Garnier & P.-M. Llorca. (2014) Efficacité et tolérance à court terme de la lurasidone dans la prise en charge de la schizophrénie. L'Encéphale 40:6, pages 507-517.
Crossref
Crossref
Ricardo P. Garay, Pierre-Michel Llorca, Allan H. Young, Ahcène Hameg & Ludovic Samalin. (2014) Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discovery Today 19:11, pages 1792-1800.
Crossref
Crossref
J. Peuskens, L. Pani, J. Detraux & M. De Hert. (2014) The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs.
Crossref
Crossref
Melvin George, Radhika Amrutheshwar, Ravi Philip Rajkumar, Shivanand Kattimani & Steven Aibor Dkhar. (2013) Newer antipsychotics and upcoming molecules for schizophrenia. European Journal of Clinical Pharmacology 69:8, pages 1497-1509.
Crossref
Crossref
Lorna Donnelly & Stephanie Sampson. (2013) Lurasidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Andrew J. Cutler, Amir H. Kalali, Greg W. Mattingly, Jelena Kunovac & Xiangyi Meng. (2013) Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectrums 18:1, pages 43-54.
Crossref
Crossref
Osamu Ichikawa, Kazuhiko Okazaki, Hiroyuki Nakahira, Megumi Maruyama, Ryu Nagata, Kumiko Tokuda, Tomoko Horisawa & Kazuto Yamazaki. (2012) Structural insight into receptor-selectivity for lurasidone. Neurochemistry International 61:7, pages 1133-1143.
Crossref
Crossref
Claudia F. Baldassano, Alexander Hosey & Jordan Coello. (2011) Bipolar Depression: An Evidence-Based Approach. Current Psychiatry Reports 13:6, pages 483-487.
Crossref
Crossref
Debbi A. Morrissette & Stephen M. Stahl. (2011) Affective symptoms in schizophrenia. Drug Discovery Today: Therapeutic Strategies 8:1-2, pages 3-9.
Crossref
Crossref